title: The burden of proof in the design of early phase clinical trials.
authors.forename: J D
authors.initials: JD
authors.lastname: Schold
mesh_terms: D000077944:Alefacept; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D009173:Mycophenolic Acid; D016559:Tacrolimus; D008775:Methylprednisolone